Subgroup analyses
| Subgroup analysis | ACS | DAPT | E/O/L | P/R |
|---|---|---|---|---|
| Number of patients | PPI: 37 015 No PPI: 77 060 | PPI: 38 244 No PPI: 40 604 | PPI: 23 437 No PPI: 33 000 | PPI: 3008 No PPI: 28 772 |
| Studies included Outcomes | Bhurke et al,30 Evanchan et al,50 Gaspar et al,52 Goodman et al,68 Ho et al,49 Hsiao et al,69 Lin et al,71 O'Donoghue et al,66 Ortolani et al,59 Simon et al,22 Valkhoff et al,47 Wu et al,56 Zou et al,36 | Aihara et al,70 Bhatt et al,7 Burkard et al,67 Ching et al,48 Chitose et al,65 Douglas et al,31 Gaglia et al,51 Gaspar et al,52 Goodman et al,68 Gupta et al,53 Harjai et al,19 Hauptle et al,33 Hokimoto and Ogawa,61 Hsiao et al,69 Hudzik et al,62 Jiang et al,34 Nakayama et al,35 O'Donoghue et al,66 Ortolani et al,59 Rossini et al,64 Tentzeris et al,55 Yasu et al,57 Zairis et al,60 Zou et al,36 | Bhatt et al,7 Douglas et al,31 Gaglia et al,51 Harjai et al,19 Hsu et al,24 Hsu,72 Hudzik et al,62 Jiang et al,34 Rossini et al,64 Valkhoff et al,47 Zairis et al,60 | Douglas et al,31 Gaglia et al,51 Hokimoto and Ogawa,61 Rossini et al,64 Valkhoff et al,47 Yasu et al,57 |
| All-cause mortality | OR 1.14; CI 0.94 to 1.39; p=0.19 | OR 1.32; CI 1.10 to 1.58; p=0.003 | OR 1.23; CI 0.72 to 2.10; p=0.46 | OR 2.01; CI 1.20 to 3.35; p=0.008 |
| CV mortality | OR 0.99; CI 0.70 to 1.39; p=0.95 | OR 1.16; CI 0.95 to 1.42; p=0.14 | OR 1.28; CI 1.14 to 1.43; p<0.001 | OR 1.96; CI 0.68 to 5.64; p=0.21 |
| ACS | OR 1.91; CI 0.89 to 4.06; p=0.09 | OR 2.37; CI 1.36 to 4.13; p=0.002 | NA | NA |
| MI | OR 1.41; CI 1.08 to 1.85; p=0.01 | OR 1.25; CI 1.07 to 1.45; p=0.005 | OR 1.25; CI 1.09 to 1.44; p=0.002 | OR 2.13; CI 1.60 to 2.85; p<0.001 |
| ST (possible/probable/definite) | NA | OR 1.36; CI 1.10 to 1.68; p=0.005 | OR 1.08; CI 0.67 to 1.73; p=0.76 | OR 2.28; CI 0.66 to 7.89; p=0.20 |
| Revascularisation | OR 1.38; CI 0.82 to 2.30; p=0.22 | OR 1.30; CI 1.08 to 1.58; p=0.006 | OR 1.06; CI 0.73 to 1.54; p=0.74 | NA |
| CVA | NA | OR 1.75; CI 0.98 to 3.16; p=0.06 | OR 2.24; CI 0.62 to 8.11; p=0.22 | NA |
| GI bleed | NA | OR 0.31; CI 0.15 to 0.65; p=0.002 | OR 0.17; CI 0.08 to 0.36; p<0.001 | NA |
References are shown in table 1.
ACS: acute coronary syndrome; CV: cardiovascular; CVA: cerebrovascular accident; DAPT: dual antiplatelet therapy; E: esomeprazole; GI: gastrointestinal; L: lansoprazole; MI: myocardial infarction; NA: not available or not applicable; O: omeprazole; P: pantoprazole; PPI: proton pump inhibitor; R: rabeprazole; ST: stent thrombosis.